OUT OF POCKET RESOURCE for SAPHNELO

December 18, 2023

SAPHNELO Access 360 12/12/23

Over 93% of Commercial Patients Enrolled in the Co-Pay Savings Program Pay $0* for SAPHNELO^₁

Help commercial patients start SAPHNELO today at no cost.†

To learn more, click here!

*Patients with commercial health insurance receive up to $16,500 per calendar year in assistance for out-of-pocket expenses. Full details are included in the Terms of Use section in the linked resource. In addition to the cost of the product itself, the out-of-pocket costs covered by the program can include the cost of infusion administration up to a maximum of $150 per infusion.‡§

†For eligible commercially insured patients only. Subject to applicable insurance plan’s eligibility rules and requirements; restrictions may apply.

‡Patients are responsible for any cost associated with the infusion administration above the $150 per infusion administration provided by the program.

§Patients who are residents of Massachusetts and Rhode Island are not eligible for infusion administration assistance.

Reference: 1. Data on File, US-75701, AstraZeneca Pharmaceuticals LP.

For US Healthcare Professionals.

SAPHNELO is a registered trademark and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies.

OUT OF POCKET RESOURCE for SAPHNELO (anifrolumab-fnia)